Investor Presentaiton slide image

Investor Presentaiton

Clear path to organic growth in the upper end of the 7-9% range in the outer part of Strive25 24 7-8% Strive 25 ambition: Strive 25 ambition: 10%+ organic growth in Double-digit organic US Chronic Care growth above the market in China Chronic Care Strive 25 ambition: Launch of the Clinical Performance Programme (Luja™ and Heylo™) Organic growth of 8-10% 7-9% FY 22/23 US China Innovation Voice & Respiratory Care Revenue growth outlook 24/25 Coloplast
View entire presentation